Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Neurocrine Biosciences, Inc. at current levels.
INGREZZA is the cash engine, but the muscarinic schizophrenia bet with AbbVie is what re-rates this from specialty pharma to CNS platform.
Where NBIX is headed
Neurocrine in mid-2028 looks like a company running two businesses in parallel. The first is the INGREZZA franchise, which is doing something over $3 billion in annual sales by then, with CRENESSITY layering another $600-800m in orphan endocrine revenue as the CAH launch matures and pediatric label expansion lands. That business alone, at high-teens revenue growth and 25%+ operating margins, is worth roughly what the equity trades at today. The second business is the CNS pipeline, and this is where the stock either becomes a $30 billion company or drifts sideways for years.
Read the full Compass Direction on NBIX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $170.00).
See the full NBIX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Neurocrine Biosciences, Inc. at current levels. INGREZZA is the cash engine, but the muscarinic schizophrenia bet with AbbVie is what re-rates this from specialty pharma to CNS platform.
What is NBIX's Compass Score?
Neurocrine Biosciences, Inc. scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for NBIX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the NBIX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.